Country's largest drug maker, Ranbaxy, on Thursday announced the launch of 'BONISTA- Teriparatide' injection used in the treatment of Osteoporosis disease in collaboration with Hyderabad-based Virchow Biotech. BONISTA- Teriparatide injection is manufactured by recombinant human parathyroid hormone and Ranbaxy has become first company in the world to launch this bio-generic product, the company said in a filing to the BSE.

MP's small and medium drug manufacturers, which are mainly located in Indore and Pithampur, are crying themselves hoarse due to the huge business losses being incurred due to non clearance and non-app

In a move likely to influence future drug price regulation in the country, the National Pharmaceutical Pricing Authority (NPPA) has started a process to understand how other countries carry out this f

Justice S Ravinder Bhat of the Delhi High Court is a hero to some.

Novartis India is up in arms against a two-month old decision of the National Pharmaceutical Pricing Authority (NPPA) to reduce the price of its flagship brand Voveran on public interest grounds.

The lead outside investigator on a crucial trial of two widely used anti-cholesterol drugs said in an e-mail message in July that Merck and Schering-Plough, the companies that make the drugs, were deliberately delaying the release of the trial results "to hide something."

Currently, there is a debate on what impact the implementation of the Trade Related Aspects of Intellectual Property Rights (TRIPS) in India would have on its pharmaceutical industry and health care. The debate hinges primarily on two major questions. First, will the new patent regime provide an impetus for innovation in the pharmaceutical industry? Second, how far will India's pharmaceutical exports of copied versions of patented drugs to developing countries be restricted under the new regime?

pharmaceutical giant GlaxoSmithKline is recalling its malaria drug Lapdap and has discontinued development of another malaria drug, Dacart, saying the drugs can lead to anaemia in some patients.

The Special Economic Zone (SEZ) imbroglio in Goa has taken a legal turn.

Hundreds of Japanese people accidentally infected with hepatitis C between the 1970s and 1990s are to be awarded compensation from the government and the drug companies responsible. But thousands of others also affected by the scandal stand to get nothing.

Pages